<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048719</url>
  </required_header>
  <id_info>
    <org_study_id>17787</org_study_id>
    <secondary_id>J2A-MC-GZGE</secondary_id>
    <secondary_id>2021-002806-29</secondary_id>
    <nct_id>NCT05048719</nct_id>
  </id_info>
  <brief_title>A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in&#xD;
      participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on&#xD;
      diet and exercise alone or on a stable dose of metformin. This study will last about 30&#xD;
      weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">August 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c) in LY3502970 and Placebo</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Change from Baseline in HbA1c in LY3502970 and Placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HbA1c in LY3502970 and Dulaglutide</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Change from Baseline in HbA1c in LY3502970 and Dulaglutide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HbA1c ≤ 6.5%</measure>
    <time_frame>Week 26</time_frame>
    <description>Percentage of Participants with HbA1c ≤ 6.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HbA1c &lt;7.0%</measure>
    <time_frame>Week 26</time_frame>
    <description>Percentage of Participants with HbA1c &lt;7.0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Fasting Glucose</measure>
    <time_frame>Week 26</time_frame>
    <description>Percentage of Participants in Fasting Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Change from Baseline in Body Weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970</measure>
    <time_frame>Baseline through Week 26</time_frame>
    <description>PK: Steady State AUC of LY3502970</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>LY3502970 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalated doses of LY3502970 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalated doses of LY3502970 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalated doses of LY3502970 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalated doses of LY3502970 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalated doses of LY3502970 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Dulaglutide subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Matching LY3502970</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching LY3502970 orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Matching Dulaglutide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching Dulaglutide subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3502970</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3502970 Dose 1</arm_group_label>
    <arm_group_label>LY3502970 Dose 2</arm_group_label>
    <arm_group_label>LY3502970 Dose 3</arm_group_label>
    <arm_group_label>LY3502970 Dose 4</arm_group_label>
    <arm_group_label>LY3502970 Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Dulaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo Matching LY3502970</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Placebo Matching Dulaglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have been diagnosed with Type 2 Diabetes on diet and exercise and/or a stable dose of&#xD;
             metformin&#xD;
&#xD;
          -  Have a stable body weight for the 3 months prior to randomization&#xD;
&#xD;
          -  Have a body mass index (BMI) ≥23 kilogram/square meter (kg/m²)&#xD;
&#xD;
          -  Males must agree to use highly effective methods of contraception&#xD;
&#xD;
          -  Women not of childbearing potential (WNOCBP) may participate in this trial&#xD;
&#xD;
          -  Note: Hormone replacement therapy in post-menopausal women is allowed but women must&#xD;
             be on stable therapy for 3 months prior to day 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have Type 1 diabetes mellitus (T1DM) or history of ketoacidosis or hyperosmolar coma&#xD;
&#xD;
          -  Have a history of diabetic retinopathy, diabetic maculopathy, or severe&#xD;
             non-proliferative diabetic retinopathy that requires immediate treatment intervention&#xD;
&#xD;
          -  Have had more than 1 episode of severe hypoglycemia and aware of hypoglycemic symptoms&#xD;
&#xD;
          -  Have acute or chronic pancreatitis&#xD;
&#xD;
          -  Have obesity induced other endocrine disorders (Cushing's syndrome or Prader - Willi&#xD;
             syndrome)&#xD;
&#xD;
          -  Have gastric emptying abnormality or chronically take medications impacting GI&#xD;
             motility&#xD;
&#xD;
          -  Have poorly controlled hypertension&#xD;
&#xD;
          -  Have the following heart conditions within the last 6 months: myocardial infarction&#xD;
             (MI), unstable angina, coronary artery bypass graft, percutaneous coronary&#xD;
             intervention (diagnostic angiograms are permitted), transient ischemic attack (TIA),&#xD;
             cerebrovascular accident (stroke)or decompensated congestive heart failure, or IV&#xD;
             heart failure&#xD;
&#xD;
          -  Have any symptoms of other liver diseases besides nonalcoholic fatty liver disease&#xD;
             (NAFLD)&#xD;
&#xD;
          -  Have HIV, or Hepatitis B or Hepatitis C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 10877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7147747777</phone>
    </contact>
    <investigator>
      <last_name>Amina Zakaria Haggag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>323-588-1968</phone>
    </contact>
    <investigator>
      <last_name>Stanley H. Hsia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>2134132500</phone>
    </contact>
    <investigator>
      <last_name>Juan Pablo Frias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rancho Cucamonga Clinical Research</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>909-941-3985</phone>
    </contact>
    <investigator>
      <last_name>Steven H. Barag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Touro University California</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94592</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>740-707-3311</phone>
    </contact>
    <investigator>
      <last_name>jay h shubrook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New West Physicians Clinical Research</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3039134159</phone>
    </contact>
    <investigator>
      <last_name>kenneth roy cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Optumcare Colorado Springs - Monument</name>
      <address>
        <city>Monument</city>
        <state>Colorado</state>
        <zip>80132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>719-488-7397</phone>
    </contact>
    <investigator>
      <last_name>Royce Keith Solano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinic</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7853680428</phone>
    </contact>
    <investigator>
      <last_name>Alan Glenn Wynne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinvest Research LLC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>417-848-1781</phone>
    </contact>
    <investigator>
      <last_name>David Gregory True</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>609-392-6666</phone>
    </contact>
    <investigator>
      <last_name>Jane L. Rohlf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intend Research, LLC</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-701-8999</phone>
    </contact>
    <investigator>
      <last_name>Lisa Connery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capital Area Research, LLC</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>717-441-1725</phone>
    </contact>
    <investigator>
      <last_name>Venkatesh K Nadar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Family Medical Associates</name>
      <address>
        <city>Levittown</city>
        <state>Pennsylvania</state>
        <zip>19056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-269-7231</phone>
    </contact>
    <investigator>
      <last_name>Kenneth E. Fox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tristar Clinical Investigations</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-831-0445</phone>
    </contact>
    <investigator>
      <last_name>Gary Yeoman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-566-7799</phone>
    </contact>
    <investigator>
      <last_name>Julio Rosenstock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>281-944-3610</phone>
    </contact>
    <investigator>
      <last_name>Syed Farhat Abbas Zaidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bandera Family Health Care</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>210-296-2445</phone>
    </contact>
    <investigator>
      <last_name>Ramon Reyes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consano Clinical Research, LLC</name>
      <address>
        <city>Shavano Park</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>210-896-7772</phone>
    </contact>
    <investigator>
      <last_name>Michelle Welch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capital Clinical Research Center</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>360-786-0692</phone>
    </contact>
    <investigator>
      <last_name>Eric J. Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastside Research Associates</name>
      <address>
        <city>Redmond</city>
        <state>Washington</state>
        <zip>98052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-751-5496</phone>
    </contact>
    <investigator>
      <last_name>Chad Crystal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bugát Pál Kórház</name>
      <address>
        <city>Gyöngyös</city>
        <state>Heves</state>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Annamária Piros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanizsai Dorottya Korhaz</name>
      <address>
        <city>Nagykanizsa</city>
        <state>Zala</state>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+36209208655</phone>
    </contact>
    <investigator>
      <last_name>Nora Kesmarki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Szent Rafael Kórház</name>
      <address>
        <city>Zalaegerszeg</city>
        <state>Zala</state>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>0036309398877</phone>
    </contact>
    <investigator>
      <last_name>Zoltan Bujtor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szent Margit Rendelőintézet Nonprofit Kft</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0036209350860</phone>
    </contact>
    <investigator>
      <last_name>Eleonora Beke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinexpert Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Filó</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ClinDiab Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+36704506822</phone>
    </contact>
    <investigator>
      <last_name>Krisztina Wudi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TRANTOR'99 Bt. Anyagcsere Centrum</name>
      <address>
        <city>Budapest</city>
        <zip>1213</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+36305983434</phone>
    </contact>
    <investigator>
      <last_name>Ildiko Szatmari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strazsahegy Medicina Bt.</name>
      <address>
        <city>Budapest</city>
        <zip>H1171</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3612570949</phone>
    </contact>
    <investigator>
      <last_name>Miklos Kajetan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Zespól Specjalistycznej Opieki Zdrowotnej</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnośląskie</state>
        <zip>50-403</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48501424165</phone>
    </contact>
    <investigator>
      <last_name>Dariusz Sowinski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabinety TERPA</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-333</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>604302289</phone>
    </contact>
    <investigator>
      <last_name>Beata Matyjaszek-Matuszek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ Medica</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-538</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48815268441</phone>
    </contact>
    <investigator>
      <last_name>Ewa Skokowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>48225081405</phone>
    </contact>
    <investigator>
      <last_name>Edward Franek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia Tuchów</name>
      <address>
        <city>Wierzchosławice</city>
        <state>Małopolskie</state>
        <zip>33-122</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Waldemar Witek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych PI-House sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>48603790004</phone>
    </contact>
    <investigator>
      <last_name>Monika Lukaszewicz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna</name>
      <address>
        <city>Lodz</city>
        <state>Łódzkie</state>
        <zip>90242</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>48604629402</phone>
    </contact>
    <investigator>
      <last_name>Malgorzata Jozefowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki</name>
      <address>
        <city>Ruda Slaska</city>
        <state>Śląskie</state>
        <zip>41-709</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48601524698</phone>
    </contact>
    <investigator>
      <last_name>Henryk Rudzki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dorado Medical Complex</name>
      <address>
        <city>Dorado</city>
        <zip>00646</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>787-383-7777</phone>
    </contact>
    <investigator>
      <last_name>Luis A Pagan-Cardona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Management Group Inc. - Hospital San Cristobal</name>
      <address>
        <city>Ponce</city>
        <zip>00780</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7879550800</phone>
    </contact>
    <investigator>
      <last_name>Javier Sosa Faria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BRCR Global Puerto Rico-Unda</name>
      <address>
        <city>San Juan</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>5614470614</phone>
    </contact>
    <investigator>
      <last_name>Roberto Unda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ambulancia diabetológie a porúch látkovej premeny a výživy - DIABEDA</name>
      <address>
        <city>Bratislava</city>
        <state>Bratislavský Kraj</state>
        <zip>831 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+421949824715</phone>
    </contact>
    <investigator>
      <last_name>Branislav Vohnout</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diacrin</name>
      <address>
        <city>Bratislava</city>
        <state>Bratislavský Kraj</state>
        <zip>841 02</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00421908956445</phone>
    </contact>
    <investigator>
      <last_name>Eva Zakovicova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetol</name>
      <address>
        <city>Prešov</city>
        <state>Prešovský Kraj</state>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+421-903-625849</phone>
    </contact>
    <investigator>
      <last_name>Marek Macko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MEDI-DIA s.r.o.</name>
      <address>
        <city>Sabinov</city>
        <state>Prešovský Kraj</state>
        <zip>083 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+421907230520</phone>
    </contact>
    <investigator>
      <last_name>Martina Merciakova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Funkystuff</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>421905547601</phone>
    </contact>
    <investigator>
      <last_name>Miriam Teplanova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DIA-MED CENTRUM s.r.o.</name>
      <address>
        <city>Puchov</city>
        <zip>020 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0907325626</phone>
    </contact>
    <investigator>
      <last_name>Ludmila Kubincova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

